Boehringer Ingelheim’s Gilotrif dose adjustments helped improve patient tolerability in certain lung cancer

Boehringer Ingelheim’s study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency and intensity of drug reactions, in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC).

Study investigator Balazs Halmos said that clinical studies have already indicated that tolerability-guided dose adjustment may be possible with Gilotrif to manage known adverse drug reactions without impacting efficacy. Halmos said that through this study, the real-world effect of tailoring the dose of Gilotrif when needed in patients with EGFR mutation-positive lung cancer is better understood.

Additionally, the study showed that there were no new safety signals, and grade 3 adverse drug events and serious adverse events occurred in 25% and 5% of participants, respectively, BI said.

“This study demonstrates the company’s ongoing commitment to support research that analyzes real-world use of Gilotrif to ensure physicians have the latest information to help address the individual needs of their patients with advanced lung cancer,” said Thomas Lechner,Therapeutic Area Head Oncology, Clinical Development & Medical Affairs Specialty Care, Boehringer Ingelheim. “The importance of real-world data for understanding the use of cancer medicines, outside of a clinical trial environment, is starting to be recognized as a valuable part of research,” he concluded.